Alejandro

Papá de un mini pig, interés en medicina interna - cardiologia

[Juan Senior @jsenior64]

Guías de falla cardiaca ESC 2026. En nuestra sección de guías de práctica clínica. No se lo pierdan. En nuestro canal de YouTube. @Medicina_UdeA

https://t.co/NIe8HdLZaW

[Ahmad Masri @MasriAhmadMD]

@DorbalaSharmila presented the results of the #REVEAL study - Evuzamitide PET/CT in cardiac amyloidosis

Amazing results of this first ever rigorously conducted multicenter trial of an imaging agent in cardiac amyloidosis

We are so thankful for the commitment of patients and investigators to the conduct of this investigator initiated trial.

Simultaneously published in @JAMA_current

https://t.co/re0HKhzOGs

#cardiotwitter
#ESC2026
#ESCCongress
#ESCCongress2026
#ESCCongressMedIQ

[Alejandro @narvaeza97]

@CircAHA @juanjpinov

[Ritu Thamman MD @iamritu]

https://t.co/NOgGkU0QVv
For aortic stenosis
🔺measure LVOT diameter 5-10 mm below annulus??
🔺this UNDERestimates SV/AVA & OVERestimates AS severity & low flow status 🆚 #WhyCMR
🔺Measure LVOT diameter at annulus: agrees best with #WhyCMR SV & AVA #echofirst @JournalASEcho

[John Mandrola, MD @drjohnm]

Excellent analysis of the limits of CAC testing

[Alejandro @narvaeza97]

Compartiendo en este espacio académico con el profe @jsenior64
Una discusión interesante acerca de nuevas ayudas para la aproximación de los pacientes con falla cardiaca
Muchas gracias al Dr @drsapg por la invitación y la excelente organización del evento.

[Edgar Argulian @argulian]

Asymmetric septal hypertrophy (ASH) is often viewed as a hallmark of hypertrophic cardiomyopathy. This study shows that while ASH (wall thickness ≥15 mm; septal/lateral ratio ≥1.3) is more common in HCM, it is not specific and is prevalent across diverse cardiac conditions.

https://t.co/FwOWvRSsBr

[Alejandro @narvaeza97]

@rajivasr @ecgrhythms Pulse tapping artifact @FelipeLozanoPi1 normal III suggest that right electrode is the culprit… but I will look for another explanation for precordial TWI

[Henry Han @HanCardiomd]

#ZEUS phase 3 trial of ziltivekimab missed its primary endpoint.

I’m still excited to see the results from the ongoing #ARTEMIS and #HERMES trials

#ARTEMIS (NCT06118281)
ARTEMIS – Effects of Ziltivekimab Versus Placebo on CV Outcomes in Patients With #AMI
https://t.co/al9x4tJurk

#HERMES: Effects Of Ziltivekimab Versus Placebo On Morbidity And Mortality In Patients With Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation
https://t.co/QND0wNB8Ou

@markcpetrie20 @mirvatalasnag @mmamas1973 @DrMarthaGulati @JamalRanaMD @GianluSava

[Pablo Corral MD @drpablocorral]

Perhaps Lp(a) should be viewed as a multidimensional particle: apo(a) contributing to thrombosis, Lp(a)-C to atherogenesis, OxPL to inflammation, and Lp(a)-TG potentially representing an additional inflammatory axis through the generation of bioactive lipolytic products. An exciting hypothesis to explore.

[EHJ Editor-in-Chief @ehj_ed]

Standard clinical and stress electrocardiogram variables to exclude left main and left main-equivalent disease. Read the results of the MASTER study just published in #EHJ

https://t.co/2kNuoaNvPN
@escardio @ESC_Journals #CardioTwitter

[Juan Senior @jsenior64]

Las guías de ICC con fracción de eyección preservada volvió costumbre recomendaciones con estudios negativos porque desenlaces secundarios o análisis pos hoc sugieren posible beneficio. Lamentable actitud. Esos resultados generan hipótesis que deben probar
https://t.co/12fCbemFTZ

[Thomas Dayspring @Drlipid]

For the deniers: This is an "Oldie but Goodie manuscript (Click to enlarge)- Written 20 years ago it noted that Optimal low-density lipoprotein is 50 to 70 mg/dl: "lower is better and PHYSIOLOGICALLY NORMAL." Note the second slide shows TC, which translates to an LDL-C between 35 and 70 mg/dL. Open access at https://t.co/vpS2Soj7cB @nationallipid @foundationofnla @society_eas @ASPCardio @escardio @atherosociety @TheEndoSociety @FamilyHeartFdn #cholesterol

[Ali Bozorgi @BozorgiAli]

Independent editorial by Prof. Boriani et al. in @Europace_ESC discusses our meta-analysis,noting ALONE-AF & OCEAN were underpowered (predominantly low-risk cohorts, few events) to settle the stroke question. Bottom line: OAC should continue post-ablation in high-risk pts. #AFib

[EHJ Editor-in-Chief @ehj_ed]

Conduction system pacing will replace conventional cardiac resynchronization therapy. Read this Great Debate just published in #EHJ
https://t.co/Axk0qTqesz
@escardio @ESC_Journals #CardioTwitter #heartfailure

[JACC Journals @JACCJournals]

Myocardial bridging, often in the mid- to distal LAD, can cause ischemia or arrhythmias under stress. Once thought benign, its impact depends on bridge depth, length, and location. Accurate anatomical and functional assessment is essential https://t.co/3iztduVrdC #JACCCaseReports

[Muthu Vaduganathan @mvaduganathan]

🔥 New in @NatureMedicine

How do you communicate lifetime benefits expected with HFpEF therapies?

New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx

#GDMT for HFpEF has finally arrived!

🔗https://t.co/ozSx3UwkLN

[Juan Senior @jsenior64]

Enfoques en cardiología:
Bloqueo interauricular
Dr Manuel Martínez-Sellés @MMSelles
Jefe de Sección de Cuidados Cardiológicos Agudos del Hospital Universitario Gregorio Marañón, Madrid, España. @Medicina_UdeA
https://t.co/D9XiHDSn0L

[Ahmed Bennis MD 🫀 @drbennisahmed]

Fever in Myocardial Infarction-Related Cardiogenic Shock

Fever in AMI-CS is common and is associated with greater illness severity but seems to be noninfectious in most cases. Further research should focus on improving antibiotic use in this population
@JACCJournals @ACCinTouch @ESC_Journals @escardio @CMichaelGibson @DrMarthaGulati @hvanspall @gcfmd @ankeetbhatt @AndrewJSauer @Hragy @iamritu @BiykemB

https://t.co/HgGAt6wCnn

[Alejandro @narvaeza97]

https://t.co/q7Vn41L8VZ

130/80 no es aceptable para muchos, todo dependerá del riesgo (así como en lípidos)

Cada vez mas estrictos con las metas, con miras a lograr un mayor impacto en la prevención del riesgo CV